Clinical trial
Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers
NCT03968406 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 26, 2019
- Completion date
- October 1, 2027
- Enrollment
- 24 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
malignant female reproductive system neoplasm, recurrent cervical carcinoma, recurrent endometrial carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent vaginal carcinoma, stage iv cervical cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, stage iv uterine corpus cancer ajcc v8, stage iv vaginal cancer ajcc v8, stage iva cervical cancer ajcc v8, stage iva fallopian tube cancer ajcc v8, stage iva ovarian cancer ajcc v8, stage iva primary peritoneal cancer ajcc v8, stage iva uterine corpus cancer ajcc v8, stage iva vaginal cancer ajcc v8, stage ivb cervical cancer ajcc v8, stage ivb fallopian tube cancer ajcc v8, stage ivb ovarian cancer ajcc v8, stage ivb primary peritoneal cancer ajcc v8, stage ivb uterine corpus cancer ajcc v8, stage ivb vaginal cancer ajcc v8